New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma

被引：24

作者：

Carlino, Matteo S. ^{[1
,2
,3
]}

Kwan, Vu ^{[3
]}

Miller, David K. ^{[4
,5
]}

Saunders, Catherine A. B. ^{[3
]}

Yip, Desmond ^{[6
,7
]}

Nagrial, Adnan M. ^{[8
]}

Tomlinson, Jeanne ^{[3
]}

Grimmond, Sean M. ^{[4
,5
]}

Scolyer, Richard A. ^{[9
,10
]}

Kefford, Richard F. ^{[1
,2
,3
,9
]}

Biankin, Andrew V. ^{[8
,11
,12
,13
]}

Long, Georgina V. ^{[9
,14
,15
]}

机构：

[1] Univ Sydney Westmead, Westmead Inst Canc Res, Sydney, NSW, Australia

[2] Millennium Inst, Sydney, NSW, Australia

[3] Westmead Hosp, Sydney, NSW, Australia

[4] Queensland Ctr Med Genom, Brisbane, Qld, Australia

[5] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia

[6] Canberra Hosp, Canberra, ACT, Australia

[7] Australian Natl Univ, Sch Med, Canberra, ACT, Australia

[8] Kinghorn Canc Ctr, Garvan Inst Med Res, Sydney, NSW, Australia

[9] Melanoma Inst Australia, Sydney, NSW, Australia

[10] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[11] Univ New S Wales, South Western Sydney Clin Sch, Liverpool, Merseyside, England

[12] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland

[13] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland

[14] Univ Sydney, Sydney, NSW 2006, Australia

[15] Westmead Inst Canc Res, Sydney, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 11期

基金：

英国惠康基金;

关键词：

IMPROVED SURVIVAL; PROGRESSION; VEMURAFENIB; MUTATIONS;

D O I：

10.1200/JCO.2013.51.5783

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E52 / E56

页数：5

共 50 条

[31] Cytokine Release Syndrome in a Patient with metastatic Melanoma under BRAF/MEK Inhibition
Dorschner, M.
Thiem, A.
Panzer, R.
Rode, S.
Emmert, S.
Tietze, J.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 46 - 46
[32] Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients
Sponghini, Andrea P.
Platini, Francesca
Marra, Elena
Rondonotti, David
Alabiso, Oscar
Fierro, Maria T.
Savoia, Paola
Stratica, Florian
Quaglino, Pietro
JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
[33] Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
Broman, Kristy Kummerow
Dossett, Lesly A.
Sun, James
Eroglu, Zeynep
Zager, Jonathan S.
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (05) : 381 - 392
[34] Cytokine Release Syndromes in a Patient with metastatic Melanoma under BRAF/MEK Inhibition
Dorschner, M.
Thiem, A.
Riedmiller-Schraven, A. -L.
Emmert, S.
Tietze, J. K.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 3 - 3
[35] BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
Zhang, Simeng
Yang, Zichang
Cheng, Yu
Guo, Xiaoyu
Liu, Chang
Wang, Shuo
Zhang, Lingyun
FRONTIERS IN PHARMACOLOGY, 2023, 13
[36] Survival and Early FDG PET Response to BRAF and MEK Inhibition in Patients with BRAF-mutant Melanoma
Schmitt, Ronald
Kreidler, Sarah
Glueck, Deborah
Amaria, Rodabe
Gonzalez, Rene
Lewis, Karl
Bagrosky, Brian
Kwak, Jennifer
Koo, Phillip
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
[37] Combined PKC and MEK inhibition for treating metastatic uveal melanoma
M S Sagoo
J W Harbour
J Stebbing
A M Bowcock
Oncogene, 2014, 33 : 4722 - 4723
[38] Combined PKC and MEK inhibition for treating metastatic uveal melanoma
Sagoo, M. S.
Harbour, J. W.
Stebbing, J.
Bowcock, A. M.
ONCOGENE, 2014, 33 (39) : 4722 - 4723
[39] Inhibition of mutant BRAF kinase in metastatic melanoma Paradoxical stimulation of avoided
Wilhelm, Martin
MEDIZINISCHE KLINIK, 2010, 105 (12) : 937 - 938
[40] BRAF Inhibition for metastatic Melanoma
Hauschild, A.
HNO, 2019, 67 (04) : 238 - 238

← 1 2 3 4 5 →